Evidence map›Paper›PMID 39258041›Full record

ArticleCureus2024

Remimazolam Anesthesia for a Pediatric Patient With Glutaric Aciduria Type I: A Case Report.

Tomoko Tsuruno, Hiroki Tateiwa, Yuki Hashimoto, Yoshifumi Katsumata, Takashi Kawano

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomoko TsurunoDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, JPN.
Hiroki TateiwaDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, JPN.
Yuki HashimotoDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, JPN.
Yoshifumi KatsumataDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, JPN.
Takashi KawanoDepartment of Anesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutaric aciduria type I (GA-1) is a rare metabolic disorder caused by an autosomal, recessive, inherited deficiency of glutaryl-CoA dehydrogenase. Reports on the anesthetic management of patients with GA-1 are limited. It has been suggested that inhalation anesthesia is safer than propofol due to the mitochondrial dysfunction inherent in GA-1. However, inhalation anesthesia poses a risk, albeit rare, of malignant hyperthermia, which can result in severe neurological damage in GA-1 patients. Therefore, we considered that management using remimazolam might be effective and, provided a successful general anesthesia using it for a pediatric patient with GA-1. We report a case of a four-year-old girl with GA-1 who underwent a laparoscopic gastrostomy under general anesthesia. Remimazolam was used for both induction and maintenance of anesthesia. Our perioperative management also included measures to prevent a hypercatabolic condition such as adequate hydration and blood glucose control. The patient had an uneventful perioperative course and was discharged on postoperative day 7. Thus, remimazolam is proposed as a new option for anesthetic management in patients with GA-1. Additionally, tailored perioperative management that addresses the unique characteristics of GA-1 is crucial for favorable outcomes.

Indexed as

general anesthesiaglutaric aciduria type 1mitochondrial disorderperioperative managementremimazolam

Identifiers

PMID39258041
PMCPMC11386074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.